Cognition Therapeutics

Cognition Therapeutics, Inc. is a clinical stage neuroscience company. The firm develops drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano in 2007 and is headquartered in Purchase, NY.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer’s disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.

PURCHASE, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, provided a recap of the virtual KOL event hosted on April 12, 2024 featuring Martin J. Sadowski, MD, PhD, DSci of the NYU School of Medicine; Anton Porsteinsson, MD of the University of Rochester Alzheimer's Disease Care, Research and Education Program; and Everard (Jort) Vijverberg, MD, PhD of the Alzheimer Center Amsterdam and Neuroscience Amsterdam.

Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's Disease

PURCHASE, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced today that the Company's president and CEO, Lisa Ricciardi, will present at the 23rd Annual Needham Virtual Healthcare Conference taking place April 8-11, 2024. During her presentation, Ms. Ricciardi will review recent corporate accomplishments and anticipated clinical milestones.

Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced it will host a virtual KOL event on Friday, April 12, 2024 from 8:00 AM to 9:30 AM ET. The live and archived event may be accessed from the investor relations section of the Cognition website. To register, please click here .

Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer's Disease on April 12, 2024

Cognition Therapeutics, Inc. (CGTX) Q4 2023 Earnings Call Transcript

- Topline Results from SHINE Study in Mild-to-Moderate Alzheimer's Expected mid-2024 - - On Track to Report Topline Results from SHIMMER Study in Mild-to-Moderate DLB in 2H 2024 - - 1Q 2024 Capital Raise Extends Cash Runway Through May 2025 - - Webcast Conference Call Scheduled Today at 8:00 a.m. ET -

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

PURCHASE, N.Y., March 15, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing product candidates designed to treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2023 on Tuesday, March 26, 2024 before the market open.

Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results

PURCHASE, N.Y., March 14, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced today the closing of its previously announced underwritten public offering of 6,571,428 shares of its common stock. Each share of common stock was sold at a price to the public of $1.75 per share. The gross proceeds to the Company from the offering were approximately $11.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from this offering to fund research, clinical development, process development and manufacturing of Cognition's product candidates, working capital, capital expenditures and other general corporate purposes.

Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock

PURCHASE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, today announced that it has priced an underwritten public offering of 6,571,428 shares of its common stock at an offering price of $1.75 per share of common stock. Cognition has also granted the underwriters a 30-day option to purchase up to 985,714 additional shares of its common stock sold in the offering on the same terms and conditions. The Company expects to close the offering on March 14, 2024, subject to the satisfaction of customary closing conditions.

Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock

PURCHASE, N. Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, today announced that it has commenced an underwritten public offering (the “offering”) of shares of its common stock. Cognition also intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the aggregate number of shares of its common stock to be sold in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares of common stock to be sold in the proposed offering will be sold by Cognition.

Cognition Therapeutics Announces Proposed Public Offering of Common Stock

PITTSBURGH, March 06, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), is presenting results of proteomic and correlation analyses of two completed clinical studies at the AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference (March 5-9, 2024 in Lisbon, Portugal). The three posters, which are listed below, summarize proteomic analyses from the completed SEQUEL and SPARC studies, which were conducted in adults with mild-to-moderate Alzheimer's disease.

Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer's Disease Studies

PURCHASE, N.Y., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced today that the Company's president and CEO, Lisa Ricciardi will present at the TD Cowen 44th Annual Health Care Conference taking place March 4-6, 2024. During her presentation, Ms. Ricciardi will highlight Cognition's pipeline progress, including upcoming clinical milestones and recent corporate achievements.

Cognition Therapeutics to Present at the TD Cowen Health Care Conference

NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that collaborators at the University of Edinburgh, Scotland published findings in the journal, Acta Neuropathologica, ( doi: 10.1007/s00401-023-02679-6 ) that provide new insight into the biology of Alzheimer's disease that is consistent with our understanding of the role the σ-2 receptor has in regulating Aβ oligomer binding.

New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812

Topline data from Phase 2 SHINE trial in patients with mild-to-moderate Alzheimer's disease anticipated in mid 2024

Cognition Therapeutics CEO Issues Letter to Shareholders

PURCHASE, N.Y., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its seventh Conversations video podcast episode: “Quantitative EEG - Effects of CT1812 on Measures of Synaptic Function in Alzheimer's Disease.” This episode will feature a review and interactive discussion of the results from Cognition's Phase 2 SEQUEL study, which were presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference.

Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) is presenting in vivo preclinical results at the Society for Neuroscience's annual meeting illuminating the role of sigma-2 (σ-2) receptor modulators, including CT1812, in models of Alzheimer's and Parkinson's diseases.

Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer's and Parkinson's Diseases

- Top-line results expected mid 2024 - - Strong physician interest drove SHINE study completion - PURCHASE, N.Y., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), (the “Company” or “Cognition”), today announced that the last participant was randomized in the Phase 2 SHINE study ( NCT03507790 ) of CT1812, the company's lead candidate for the treatment of age-related neurodegenerative diseases of the CNS and retina.

Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease

Phase 2 trials in mild-to-moderate Alzheimer's disease and dementia with Lewy bodies advancing Clinical site initiation underway in 540-patient early stage Alzheimer's disease START trial; will permit approved monoclonal antibody (lecanemab) as combination therapy Complete data from CT1812 SEQUEL EEG study and Phase 2 study design of START trial  presented at CTAD 2023 Initiated dosing in MAGNIFY trial for geographic atrophy secondary to dry age-macular degeneration (dry AMD) PURCHASE, N.Y., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc.  (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today reported financial results for the third quarter ended September 30, 2023 and provided recent business updates.

Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that Christoper van Dyck, M.D., the director of the Yale Alzheimer's Disease Research Unit and the Yale Alzheimer's Disease Research Center, is presenting the Phase 2 study design of the company's ongoing START study in an oral late-breaking session at Clinical Trials on Alzheimer's Disease (CTAD) conference. The START Study is assessing once-daily oral CT1812 or placebo in 540 individuals with early Alzheimer's disease for 18 months of treatment. Cognition Therapeutics is conducting the study in collaboration with the Alzheimer's Clinical Trials Consortium (ACTC) with major grant support from the National Institute of Aging (NIA) at the National Institutes of Health.

Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer's Disease at CTAD

PURCHASE, N.Y., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) announced that Willem de Haan, M.D., Ph.D., a neurologist and senior researcher at the Amsterdam University Medical Centers' Alzheimer Center, is presenting complete EEG findings from the Phase 2 SEQUEL study at the Clinical Trials on Alzheimer's Disease (CTAD) conference. SEQUEL was conducted at the Amsterdam UMC in the Netherlands with Everard (Jort) Vijverberg, M.D., Ph.D., acting as principal investigator. The poster describing changes in brain wave patterns in adults with mild-to-moderate Alzheimer's disease following 28-days of treatment with CT1812 or placebo will be on display through the conclusion of CTAD.

Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at CTAD

Complete EEG results from SEQUEL study to be unveiled,  demonstrating beneficial impact of CT1812 on brain synaptic function CT1812 START study in early Alzheimer's disease allows approved monoclonal antibody as background therapy – featured as late-breaking, oral presentation PURCHASE, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) announced upcoming presentations from studies of CT1812, the Company's lead candidate for the treatment of adults with early, mild and moderate Alzheimer's disease at the Clinical Trials on Alzheimer's Disease (CTAD) conference being held October 24-27, 2023 virtually and in person in Boston, MA.

Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications

PURCHASE, N.Y., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its sixth “Conversations” video podcast, which features an interactive discussion with retinal specialists about dry age-related macular degeneration (dry AMD) and the current treatment landscape. Dry AMD is caused by a degeneration of the macula and gradual loss of central vision. An estimated 1.5 million people in the United States are affected by late-stage dry AMD, which can result in permanent vision loss.

Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMD

PURCHASE, N.Y., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc.  (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), announced that Lisa Ricciardi, Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright Annual Global Investment Conference and participating on a panel at the Cantor Fitzgerald Global Healthcare Conference in September 2023. In addition, she will be moderating a panel on pipeline prioritization strategies at the Longwood Healthcare Leaders Fall Conference, a brainstorming forum of pharmaceutical, healthcare and investment leaders focused on accelerating the translation of discoveries into medicines.

Cognition Therapeutics Announces Participation in Upcoming September Conferences

Cognition Therapeutics, Inc. (NASDAQ:CGTX ) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Daniel Kontoh-Boateng - Investor Relations Lisa Ricciardi - President and Chief Executive Officer John Doyle - Chief Financial Officer Tony Caggiano - Chief Medical Officer and Head, R&D Conference Call Participants Charles Duncan - Cantor Jay Olson - Oppenheimer Aydin Huseynov - Ladenburg Operator Good morning, ladies and gentlemen and welcome to Cognition Therapeutics Second Quarter 2023 Earnings Conference Call. My name is Jenny and I will be your conference operator today.

Cognition Therapeutics, Inc. (CGTX) Q2 2023 Earnings Call Transcript

Announced Positive Topline Results from CT1812 Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer's Disease Commenced Recruitment for 540-patient Phase 2 START Trial in Early Alzheimer's Disease Published Data from SNAP Study Affirming Target Engagement of Sigma-2 (σ-2) Receptor Patient Dosing Commenced in MAGNIFY Study for Geographic Atrophy PURCHASE, N.Y., Aug. 08, 2023 (GLOBE NEWSWIRE) --   Cognition Therapeutics, Inc.  (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today reported financial results for the second quarter ended June 30, 2023 and provided recent business updates.

Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

PURCHASE, N.Y., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc.  (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today announced that the Company will release financial results for the second quarter on Tuesday, August 8, 2023 before the market opens. Following the release, management will host a conference call at 8:00 a.m. ET on the same day to review financial results and provide a business update.

News for Cognition Therapeutics Stock (CGTX)